Ijeoma Edoka1, Heather Fraser1, Lise Jamieson2, Gesine Meyer-Rath2,3, Winfrida Mdewa1. 1. SAMRC Centre for Health Economics and Decision Science-PRICELESS SA, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3. Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) has had a devastating impact globally, with severe health and economic consequences. To prepare health systems to deal with the pandemic, epidemiological and cost projection models are required to inform budgets and efficient allocation of resources. This study estimates daily inpatient care costs of COVID-19 in South Africa, an important input into cost projection and economic evaluation models. METHODS: We adopted a micro-costing approach, which involved the identification, measurement and valuation of resources used in the clinical management of COVID-19. We considered only direct medical costs for an episode of hospitalisation from the South African public health system perspective. Resource quantities and unit costs were obtained from various sources. Inpatient costs per patient day was estimated for consumables, capital equipment and human resources for three levels of inpatient care - general wards, high care wards and intensive care units (ICUs). RESULTS: Average daily costs per patient increased with the level of care. The highest average daily cost was estimated for ICU admissions - 271 USD to 306 USD (financial costs) and ~800 USD to 830 USD (economic costs, excluding facility fee) depending on the need for invasive vs. non-invasive ventilation (NIV). Conversely, the lowest cost was estimated for general ward-based care - 62 USD to 79 USD (financial costs) and 119 USD to 278 USD (economic costs, excluding facility fees) depending on the need for supplemental oxygen. In high care wards, total cost was estimated at 156 USD, financial costs and 277 USD, economic costs (excluding facility fees). Probabilistic sensitivity analyses suggest our costs estimates are robust to uncertainty in cost inputs. CONCLUSION: Our estimates of inpatient costs are useful for informing budgeting and planning processes and cost-effectiveness analysis in the South African context. However, these estimates can be adapted to inform policy decisions in other context. 2021 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BACKGROUND:Coronavirus disease 2019 (COVID-19) has had a devastating impact globally, with severe health and economic consequences. To prepare health systems to deal with the pandemic, epidemiological and cost projection models are required to inform budgets and efficient allocation of resources. This study estimates daily inpatient care costs of COVID-19 in South Africa, an important input into cost projection and economic evaluation models. METHODS: We adopted a micro-costing approach, which involved the identification, measurement and valuation of resources used in the clinical management of COVID-19. We considered only direct medical costs for an episode of hospitalisation from the South African public health system perspective. Resource quantities and unit costs were obtained from various sources. Inpatient costs per patient day was estimated for consumables, capital equipment and human resources for three levels of inpatient care - general wards, high care wards and intensive care units (ICUs). RESULTS: Average daily costs per patient increased with the level of care. The highest average daily cost was estimated for ICU admissions - 271 USD to 306 USD (financial costs) and ~800 USD to 830 USD (economic costs, excluding facility fee) depending on the need for invasive vs. non-invasive ventilation (NIV). Conversely, the lowest cost was estimated for general ward-based care - 62 USD to 79 USD (financial costs) and 119 USD to 278 USD (economic costs, excluding facility fees) depending on the need for supplemental oxygen. In high care wards, total cost was estimated at 156 USD, financial costs and 277 USD, economic costs (excluding facility fees). Probabilistic sensitivity analyses suggest our costs estimates are robust to uncertainty in cost inputs. CONCLUSION: Our estimates of inpatient costs are useful for informing budgeting and planning processes and cost-effectiveness analysis in the South African context. However, these estimates can be adapted to inform policy decisions in other context. 2021 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Entities:
Keywords:
COVID-19; Economic Cost; Financial Cost; Healthcare Budget; Inpatient Cost; South Africa
Authors: Ronel Herselman; Vidya Lalloo; Veronica Ueckermann; Daniel J van Tonder; Edwin de Jager; Sandra Spijkerman; Wanda van der Merwe; Marizane du Pisane; Fanie Hattingh; David Stanton; Ross Hofmeyr Journal: Afr J Emerg Med Date: 2021-09-13
Authors: Krishna P Reddy; Kieran P Fitzmaurice; Justine A Scott; Guy Harling; Richard J Lessells; Christopher Panella; Fatma M Shebl; Kenneth A Freedberg; Mark J Siedner Journal: Nat Commun Date: 2021-10-29 Impact factor: 14.919
Authors: Paul B L George; Florent Rossi; Magali-Wen St-Germain; Pierre Amato; Thierry Badard; Michel G Bergeron; Maurice Boissinot; Steve J Charette; Brenda L Coleman; Jacques Corbeil; Alexander I Culley; Marie-Lou Gaucher; Matthieu Girard; Stéphane Godbout; Shelley P Kirychuk; André Marette; Allison McGeer; Patrick T O'Shaughnessy; E Jane Parmley; Serge Simard; Richard J Reid-Smith; Edward Topp; Luc Trudel; Maosheng Yao; Patrick Brassard; Anne-Marie Delort; Araceli D Larios; Valérie Létourneau; Valérie E Paquet; Marie-Hélène Pedneau; Émilie Pic; Brooke Thompson; Marc Veillette; Mary Thaler; Ilaria Scapino; Maria Lebeuf; Mahsa Baghdadi; Alejandra Castillo Toro; Amélia Bélanger Cayouette; Marie-Julie Dubois; Alicia F Durocher; Sarah B Girard; Andrea Katherín Carranza Diaz; Asmaâ Khalloufi; Samantha Leclerc; Joanie Lemieux; Manuel Pérez Maldonado; Geneviève Pilon; Colleen P Murphy; Charly A Notling; Daniel Ofori-Darko; Juliette Provencher; Annabelle Richer-Fortin; Nathalie Turgeon; Caroline Duchaine Journal: Antibiotics (Basel) Date: 2022-07-19